Summary

Global cell and gene therapy thawing equipment market is projected to register a CAGR of 14.2% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028
Market Segmentation:
Global Cell and Gene Therapy Thawing Equipment Market, By Modality (Benchtop and Portable), Sample (Cell Therapies and Gene Therapies), Type (Manual Thawing System and Automatic Thawing System), Application (Upstream Processing and Downstream Processing), End User (Blood Banks And Transfusion Centres, Hospitals and Diagnostic Laboratories, Research Laboratories And Academic Institutes, Biotechnology and Pharmaceutical Industry, Cord Blood and Stem Cell Banks, Gene Banks and Others), Distribution Channel (Direct Tender, Third Part Distributor and Others), Country (U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Ireland, Rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel and Rest of Middle East and Africa, Brazil, Argentina and Rest of South America) Industry Trends and Forecast to 2028

Some of the major factors contributing to the growth of the global cell and gene therapy thawing equipment market are:

• Rise in investment in research and development for development of cell and gene therapies
• Rising healthcare expenditure

Market Players:

The key market players for global cell and gene therapy thawing equipment market are listed below:

• Pluristem Therapeutics Inc.
• Genesis BPS
• Eppendorf AG
• Cytiva (A subsidiary of Danaher Corporation)
• Glenmark Pharmaceutical Inc.
• USA (A subsidiary of Glenmark)
• EDGE pharma
• Cook
• SARSTEDT AG & Co. KG
• Barkey
• Boekel Scientific
• LABCOLD
• Sartorious AG
• Helmer Scientific Inc.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET 33
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35
2 MARKET SEGMENTATION 38
2.1 MARKETS COVERED 38
2.2 GEOGRAPHICAL SCOPE 39
2.3 YEARS CONSIDERED FOR THE STUDY 40
2.4 CURRENCY AND PRICING 40
2.5 DBMR TRIPOD DATA VALIDATION MODEL 41
2.6 MULTIVARIATE MODELLING 44
2.7 TYPE LIFELINE CURVE 45
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 46
2.9 DBMR MARKET POSITION GRID 47
2.10 VENDOR SHARE ANALYSIS 48
2.11 MARKET APPLICATION COVERAGE GRID 49
2.12 SECONDARY SOURCES 50
2.13 ASSUMPTIONS 50
3 EXECUTIVE SUMMARY 51
4 PREMIUM INSIGHTS 55
5 USAGE OF THAWING EQUIPMENT IN UPSTREAM AND DOWNSTREAM PROCESSES 59
5.1 UPSTREAM PROCESS 59
5.2 DOWNSTREAM PROCESS 59
6 CELL AND GENE THERAPY WORKFLOW USING THAWING EQUIPMENT 60
 
7 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: REGULATIONS 62
7.1 CANADA 62
7.2 THE U.S. 62
7.3 EUROPE 62
7.4 GENE THERAPY LEGISLATION IN AUSTRIA 63
7.5 GENE THERAPY LEGISLATION IN BULGARIA 63
7.6 JAPAN 63
7.7 ITALY 63
7.8 MALAYSIA 63
8 REGIONAL SUMMARY 64
9 MARKET OVERVIEW 66
9.1 DRIVERS 68
9.1.1 INCREASE IN CASES OF GENETIC DISEASES SUCH AS CYSTIC FIBROSIS AND SICKLE CELL ANEMIA 68
9.1.2 RISE IN INVESTMENT IN R&D FOR DEVELOPMENT OF CELL AND GENE THERAPIES 70
9.1.3 GOVERNMENT INITIATIVES FOR INITIATION OF CELL AND GENE THERAPY FIELD 70
9.1.4 INCREASED IMPLEMENTATION OF ADENO-ASSOCIATED VIRUS 71
9.1.5 TECHNOLOGICAL ADVANCEMENTS IN THE THAWING SYSTEMS 71
9.2 RESTRAINTS 71
9.2.1 RISE IN COST ASSOCIATED WITH CELL AND GENE THERAPY ENGINEERING 71
9.2.2 RISE OF UNWANTED MUTAGENS 72
9.2.3 TECHNICAL HINDRANCE FACED IN USING THAWING INSTRUMENTS 72
9.2.4 STRICT REGULATORY FRAMEWORK 72
9.3 OPPORTUNITIES 73
9.3.1 INCREASING PREVALENCE OF CANCER 73
9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 74
9.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR 75
9.4 CHALLENGES 75
9.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES 75
9.4.2 LACK OF ACCESSIBILITY 76
10 IMPACT OF COVID-19 ON GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET 77
10.1 IMPACT ON PRICE 77
10.2 IMPACT ON DEMAND 78
10.3 IMPACT ON SUPPLY CHAIN 78
10.4 STRATEGIC DECISION FOR MANUFACTURERS 78
10.5 CONCLUSION 79
11 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY MODALITY 80
11.1 OVERVIEW 81
11.2 BENCH TOP 85
11.3 PORTABLE 85
12 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY SAMPLE 87
12.1 OVERVIEW 88
12.2 CELL THERAPIES 91
12.2.1 CAR T CELLS 92
12.2.2 NK CELLS 92
12.2.3 MSCS 92
12.2.4 TILS 92
12.2.5 OTHERS 92
12.3 GENE THERAPIES 92
12.3.1 ADENOVIRUS 93
12.3.2 ADENO-ASSOCIATED VIRUSES 93
12.3.3 LENTIVIRUSES 93
12.3.4 ONCOLYTIC VIRUSES 93
12.3.5 OTHERS 94
13 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY TYPE 95
13.1 OVERVIEW 96
13.2 AUTOMATIC THAWING SYSTEM 99
13.3 MANUAL THAWING SYSTEM 99
14 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY APPLICATION 101
14.1 OVERVIEW 102
14.2 UPSTREAM PROCESSING 104
14.2.1 AUTOMATIC THAWING SYSTEM 105
14.2.2 MANUAL THAWING SYSTEM 105
14.3 DOWNSTREAM PROCESSING 105
14.3.1 AUTOMATIC THAWING SYSTEM 106
14.3.2 MANUAL THAWING SYSTEM 106
 
15 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY END USER 107
15.1 OVERVIEW 108
15.2 HOSPITALS AND DIAGNOSTIC LABORATORIES 111
15.3 BLOOD BANKS AND TRANSFUSION CENTERS 111
15.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES 112
15.5 BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRY 113
15.6 CORD BLOOD AND STEM CELL BANKS 114
15.7 GENE BANKS 115
15.8 OTHERS 115
16 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY DISTRIBUTION CHANNEL 117
16.1 OVERVIEW 118
16.2 DIRECT TENDER 122
16.3 THIRD PARTY DISTRIBUTORS 122
16.4 OTHERS 123
17 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY REGION 124
17.1 OVERVIEW 125
17.2 NORTH AMERICA 130
17.2.1 U.S. 137
17.2.2 CANADA 140
17.2.3 MEXICO 143
17.3 EUROPE 146
17.3.1 GERMANY 153
17.3.2 FRANCE 156
17.3.3 U.K. 159
17.3.4 ITALY 162
17.3.5 SPAIN 165
17.3.6 RUSSIA 168
17.3.7 TURKEY 171
17.3.8 BELGIUM 174
17.3.9 NETHERLANDS 177
17.3.10 SWITZERLAND 180
17.3.11 LUXEMBOURG 183
17.3.12 REST OF EUROPE 186
 
17.4 ASIA-PACIFIC 187
17.4.1 CHINA 194
17.4.2 INDIA 197
17.4.3 JAPAN 200
17.4.4 SOUTH KOREA 203
17.4.5 AUSTRALIA 206
17.4.6 SINGAPORE 209
17.4.7 THAILAND 212
17.4.8 MALAYSIA 215
17.4.9 INDONESIA 218
17.4.10 PHILIPPINES 221
17.4.11 REST OF ASIA PACIFIC 224
17.5 SOUTH AMERICA 225
17.5.1 BRAZIL 232
17.5.2 ARGENTINA 235
17.5.3 REST OF SOUTH AMERICA 238
17.6 MIDDLE EAST AND AFRICA 239
17.6.1 SOUTH AFRICA 246
17.6.2 SAUDI ARABIA 249
17.6.3 U.A.E. 252
17.6.4 EGYPT 255
17.6.5 ISRAEL 258
17.6.6 REST OF MIDDLE EAST AFRICA 261
18 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, COMPANY LANDSCAPE 262
18.1 COMPANY SHARE ANALYSIS: GLOBAL 262
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 263
18.3 COMPANY SHARE ANALYSIS: EUROPE 264
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 265
19 SWOT ANALYSIS 266
20 COMPANY PROFILE 267
20.1 MERCK KGAA 267
20.1.1 COMPANY SNAPSHOT 267
20.1.2 REVENUE ANALYSIS 267
20.1.3 PRODUCT PORTFOLIO 268
20.1.4 RECENT DEVELOPMENTS 269
 
20.2 EPPENDORF AG 270
20.2.1 COMPANY SNAPSHOT 270
20.2.2 REVENUE ANALYSIS 270
20.2.3 PRODUCT PORTFOLIO 271
20.2.4 RECENT DEVELOPMENTS 271
20.3 SARTORIUS AG 273
20.3.1 COMPANY SNAPSHOT 273
20.3.2 REVENUE ANALYSIS 273
20.3.3 PRODUCT PORTFOLIO 274
20.3.4 RECENT DEVELOPMENT 274
20.4 CYTIVA (A SUBSIDIARY OF DANAHER CORPORATION) 275
20.4.1 COMPANY SNAPSHOT 275
20.4.2 REVENUE ANALYSIS 275
20.4.3 PRODUCT PORTFOLIO 276
20.4.4 .RECENT DEVELOPMENTS 277
20.5 BARKEY 278
20.5.1 COMPANY SNAPSHOT 278
20.5.2 PRODUCT PORTFOLIO 278
20.5.3 RECENT DEVELOPMENTS 278
20.6 BOEKEL SCIENTIFIC 279
20.6.1 COMPANY SNAPSHOT 279
20.6.2 PRODUCT PORTFOLIO 279
20.6.3 RECENT DEVELOPMENT 279
20.7 BIOLINE INDIA 280
20.7.1 COMPANY SNAPSHOT 280
20.7.2 PRODUCT PORTFOLIO 280
20.7.3 RECENT DEVELOPMENTS 280
20.8 COOK 281
20.8.1 COMPANY SNAPSHOT 281
20.8.2 PRODUCT PORTFOLIO 281
20.8.3 RECENT DEVELOPMENT 281
20.9 GENESIS BPS 282
20.9.1 COMPANY SNAPSHOT 282
20.9.2 PRODUCT PORTFOLIO 282
20.9.3 RECENT DEVELOPMENTS 282
20.10 HELMER SCIENTIFIC INC. 283
20.10.1 COMPANY SNAPSHOT 283
20.10.2 PRODUCT PORTFOLIO 283
20.10.3 RECENT DEVELOPMENTS 283
20.11 LABCOLD 284
20.11.1 COMPANY SNAPSHOT 284
20.11.2 PRODUCT PORTFOLIO 284
20.11.3 RECENT DEVELOPMENTS 284
20.12 PLEURISTEM THERAPEUTICS INC. 285
20.12.1 COMPANY SNAPSHOT 285
20.12.2 REVENUE ANALYSIS 285
20.12.3 PRODUCT PORTFOLIO 285
20.12.4 RECENT DEVELOPMENTS 286
20.13 SARSTEDT AG & CO. KG 287
20.13.1 COMPANY SNAPSHOT 287
20.13.2 PRODUCT PORTFOLIO 287
20.13.3 RECENT DEVELOPMENTS 287
21 QUESTIONNAIRE 288
22 RELATED REPORTS 292